ECM
NTLA icon

ETrade Capital Management’s Intellia Therapeutics NTLA Stock Holding History

ETrade Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,526
Closed -$215K – 791
2018
Q3 		$215K Buy
7,526
+47
+0.6% +$1.37K 0.01% 775
2018
Q2 		$205K Buy
+7,479
New +$181K 0.01% 754

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

ETrade Capital Management's NTLA Position: Q4 2018 in Review

ETrade Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2018, closing a stake of 7,526 shares — an estimated $215K sold.

ETrade Capital Management first reported a position in NTLA in Q2 2018 and held it in 2 quarters. The position peaked at $215K in Q3 2018. 141 funds tracked by Wall St. Rank hold NTLA as of Q4 2018.

  • ETrade Capital Management reported no remaining Intellia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • ETrade Capital Management sold 7,526 Intellia Therapeutics shares in Q4 2018, an estimated $215K.
  • ETrade Capital Management first reported a position in Intellia Therapeutics in Q2 2018 and held it in 2 quarters.
  • ETrade Capital Management's Intellia Therapeutics position peaked at $215K in Q3 2018.
  • 141 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2018.

Based on ETrade Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.